Full-Time

Associate Director

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

No salary listed

Princeton, NJ, USA

Hybrid

Category
Legal & Compliance (1)
Required Skills
Sharepoint
Veeva
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s degree in life science or closely related discipline. Advanced degree preferred (Pharm.D., Phd, M.S, JD).
  • Minimum seven (7) years of progressive experience in the pharmaceutical or biotechnology industry, specifically in Regulatory Affairs with a focus on Advertising and Promotion (Ad/Promo).
  • Proven track record as the primary regulatory reviewer for promotional and non-promotional materials across various therapeutic areas, ensuring compliance with FDA regulations, industry guidelines (e.g., OPDP, PhRMA), and internal policies.
  • Strong experience in leading and managing Regulatory review processes within cross-functional Medical, Legal, and Regulatory (MLR) teams for both consumer and professional marketing materials.
  • Familiarity with launch planning, including pre-approval communications, disease awareness campaigns, and launch materials.
  • Experience with training Commercial and cross-functional teams on promotional compliance principles, regulatory changes, and industry best practices.
  • Preferred, but not required, experience with reviewing promotional and non-promotional communications in Canada to be compliant with Health Canada regulations.
  • Thorough knowledge of applicable regulations, guidance, and industry standards related to advertising and promotional communications about prescription drugs, devices (if applicable), and investigational treatments in the US.
  • Understanding of clinical study design and statistical analyses in assessment of promotional claims.
  • Excellent written, verbal, and presentation skills, with the ability to communicate effectively across all levels of the organization.
  • Solid proficiency using Microsoft Office Suite including Word, Excel, and Power Point for documentation, analysis, and presentations.
  • Experience with Veeva, SharePoint and Box.
  • Requires up to 10% domestic and international travel.
Responsibilities
  • Independently review, approve, and monitor product advertising and promotional labeling material for an assigned product to ensure compliance with US regulatory requirements.
  • Support preparation of FDA Form 2253 submissions and any requests for advisory comment submissions to FDA's Office of Prescription Drug Promotion (OPDP) as well as submissions to PAAB for promotional materials in Canada, as applicable.
  • Provide strategic and tactical regulatory support and guidance for assigned product and disease state communications as well as pipeline and non-promotional communications.
  • Provide guidance and input for assigned development products reflective of promotional considerations, including assessment of potential labeling claims.
  • Serve as Promotional Review Committee (PRC) chair and as the primary regulatory reviewer of advertising, promotions, and other related materials for assigned product to ensure compliance with applicable FDA/Health Canada laws, regulations, and guidance.
  • Work collaboratively with cross-functional partners, including Legal and Medical as part of PRC. Develops solutions to complex promotional issues by utilizing scientific and regulatory knowledge to support business objectives and initiatives while effectively identifying, escalating, and managing business risks.
  • Serve as the regulatory reviewer for the Medical Review Process (MRC) for assigned product(s).
  • Provide direction and works collaboratively to ensure that changes in US Prescribing Information and Canadian Product Monograph are reflected in current promotions and advertising.
  • Continually assess the advertising and promotion related process to enhance efficiencies and compliance.
  • Collaborates in cross-functional efforts to develop, update, and implement policies, procedures and guidelines related to Regulatory Advertising and Promotion Compliance.
  • Primary liaison with Office of Prescription Drug Promotion (OPDP) regarding advertising and promotion for assigned products.
  • Monitors US and Canadian regulatory promotional environment and stays abreast of all relevant regulatory and industry changes and updates related to FDA and Health Canada guidance, warning letters, enforcement actions and regulations; and communicate to appropriate internal and external personnel in a timely manner, highlighting the implications of the changes.
  • Ensures the maintenance of paper and electronic records of all submissions and communications with OPDP, and any supporting documentation
  • Provide relevant regulatory compliance training to staff and cross-functional partners from a regulatory perspective.
Desired Qualifications
  • None specified

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Kyowa Kirin who can refer or advise you

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.